Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics Inc (HRTX) is a commercial-stage biotechnology company pioneering extended-release therapies through its proprietary biochronomer drug delivery platform. This page for comprehensive HRTX news provides investors and healthcare professionals with timely updates on regulatory milestones, clinical advancements, and strategic initiatives.
Access the latest press releases, financial reports, and product development updates in one centralized location. Track developments across key areas including postoperative pain management, antiemetic therapies, and novel drug delivery systems. Our curated news collection ensures you stay informed about FDA approvals, partnership announcements, and research breakthroughs.
All content is verified for accuracy and relevance, offering insights into how HRTX's innovations in sustained-release formulations are transforming acute care and oncology treatment paradigms. Bookmark this page for efficient monitoring of corporate updates that may impact clinical practice or investment considerations.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced a private placement to raise approximately $76.5 million by selling 16,129,032 shares of common stock at $3.10 per share. This funding, led by Deep Track Capital, LP, aims to support the company's acute care and oncology franchises, including the anticipated launch of HTX-019 for postoperative nausea and vomiting. The placement is expected to close on August 11, 2022. The company also plans to file a registration statement with the SEC for the resale of these shares.
Heron Therapeutics reported significant growth in the second quarter of 2022, with ZYNRELEF product sales soaring by 140% sequentially, reaching $2.5 million. The oncology care franchise saw net sales climb 12% to $25.1 million, prompting an increase in full-year sales guidance to $93 million to $95 million. The company anticipates over $50 million in cost reductions due to restructuring efforts. Pro-forma cash post-private placement stands at $158.7 million, ensuring a cash runway through 2024.
Heron Therapeutics (HRTX) will host a conference call on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and recent business developments. The call is accessible via phone or webcast, with an archive available for 60 days post-call. Heron focuses on developing therapeutic innovations to enhance medical care, particularly for acute care and oncology patients. Interested parties can find more details on the company's website.
Heron Therapeutics, Inc. (HRTX) announced a study published in the Journal of Knee Surgery evaluating the safety and efficacy of ZYNRELEF as part of a non-opioid multimodal analgesic regimen for total knee arthroplasty (TKA). The study found over 80% of patients did not experience severe pain post-surgery, with 12% remaining opioid-free. ZYNRELEF demonstrated improved pain control compared to standard treatments, showing no safety concerns. The company emphasizes the need for controlled trials to confirm these promising results and maintain ZYNRELEF's potential in outpatient settings.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced its participation in the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 8:30 am ET. The event runs from June 8-10 in New York, NY. A live webcast will be available on their website under the Investor Resources section. Heron focuses on developing therapeutic innovations to enhance medical care for patients, particularly in acute care and oncology.
Heron Therapeutics (HRTX) presented interim data from a Phase 2 study of ZYNRELEF at the SOAP 54th Annual Meeting. ZYNRELEF, approved for postoperative analgesia, showed low levels of bupivacaine and meloxicam in breast milk post-administration in women undergoing C-sections. Results indicated ZYNRELEF was well-tolerated and effectively reduced postoperative opioid use, with 27% of patients experiencing opioid-free recovery. The findings suggest ZYNRELEF could significantly enhance pain management for postpartum women while minimizing opioid exposure.
Heron Therapeutics (HRTX) reported Q1 2022 net product sales of $23.5 million, marking a year-over-year increase from $20 million. ZYNRELEF unit demand rose by 68%, supported by CMS's approval of a 3-year transitional pass-through status starting April 1, enabling separate reimbursements outside surgical bundle payments. Additionally, the company's oncology care franchise generated $22.4 million in net revenue, a 13% rise over the prior quarter, with full-year guidance set between $89 million and $93 million. However, net loss increased to $63.9 million, or $0.63 per share.
Heron Therapeutics (HRTX) announced a conference call for May 9, 2022, at 4:30 p.m. ET to discuss its first quarter financial results and recent business highlights. The call can be accessed via telephone or web, and an archive will be available for 60 days. The company is focused on developing best-in-class treatments aimed at fulfilling unmet patient needs in acute care and oncology. Caution is advised regarding forward-looking statements due to inherent risks and uncertainties.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will participate in a fireside chat at the 21st Annual Virtual Needham Healthcare Conference on April 11, 2022, at 8:00 am PT. The event aims to discuss the company's innovative approaches to addressing unmet patient needs in acute care and oncology through best-in-class treatments. A live webcast will be available on the company's website in the Investor Resources section. For more information about Heron and its products, please visit www.herontx.com.
FAQ
What is the current stock price of Heron Therapeutics (HRTX)?
What is the market cap of Heron Therapeutics (HRTX)?
